Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.37 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.36 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.36 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL632919 | 1.00 | PIK3CG (0.44) | PIK3CGADORA3SIRT2ADAMTS5HTR1A | |
| SCHEMBL29634508 | 1.00 | PIK3CG (0.44) | PIK3CGADORA3SIRT2ADAMTS5HTR1A | |
| SCHEMBL866306 | 1.00 | PIK3CG (0.44) | PIK3CGADORA3SIRT2ADAMTS5HTR1A | |
| SCHEMBL30092323 | 0.88 | SLC6A4 (0.43) | PIK3CGHTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL25666164 | 0.88 | SLC6A4 (0.43) | PIK3CGHTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL25666254 | 0.85 | HTR1A (0.47) | PIK3CGADORA3HTR1ASLC6A2SLC6A4 | |
| SCHEMBL866075 | 0.82 | ADORA3 (0.45) | PIK3CGADORA3SIRT2ADAMTS5SRD5A2 | |
| SCHEMBL14355700 | 0.80 | MAPT (0.39) | MAPTKDM4EALDH1A1POLBCA9 | |
| SCHEMBL24689334 | 0.79 | ADORA3 (0.43) | PIK3CGADORA3SIRT2LTA4HPLA2G2A | |
| SCHEMBL24689336 | 0.79 | FEN1 (0.42) | PIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115521254-B | Indanterol derivative and preparation method and application thereof | 中国药科大学 | 2024-05-31 | — | — | CN | disclosed |
| CN-115521254-A | Indanterol derivative and preparation method and application thereof | 中国药科大学 | 2022-12-27 | — | — | CN | disclosed |
| US-9040559-B2 | BETA2-adrenoceptor agonists | NOVARTIS AG (CH) | 2015-05-26 | — | — | US | disclosed |
| US-20140343091-A1 | BETA2-ADRENOCEPTOR AGONISTS | NOVARTIS AG (CH) | 2014-11-20 | — | — | US | disclosed |
| US-8796307-B2 | Beta2-adrenoreceptor agonists | NOVARTIS AG (CH) | 2014-08-05 | — | — | US | disclosed |
| US-20140066478-A1 | Beta2-Adrenoreceptor Agonists | NOVARTIS AG (CH) | 2014-03-06 | — | — | US | disclosed |
| US-8658673-B2 | BETA2-adrenoreceptor agonists | NOVARTIS AG (CH) | 2014-02-25 | — | — | US | disclosed |
| US-20130231367-A1 | BETA2-ADRENORECEPTOR AGONISTS | NOVARTIS AG (CH) | 2013-09-05 | — | — | US | disclosed |
| US-8436017-B2 | Beta-2-adrenoreceptor agonists | NOVARTIS AG (CH) | 2013-05-07 | — | — | US | disclosed |
| EP-2332915-B1 | Beta2-adrenoceptor agonists | NOVARTIS AG (CH) | 2013-02-27 | — | — | EP | disclosed |
| EP-2332915-A1 | Beta2-adrenoceptor agonists | Novartis AG (CH) | 2011-06-15 | — | — | EP | disclosed |
| US-20110034509-A1 | Beta-2-Adrenoreceptor Agonists | CUENOUD BERNARD | 2011-02-10 | — | — | US | disclosed |
| US-7820694-B2 | Administering an aminoindanyl derivative and; a steroid, dopamine receptor agonist or an anticholinergic or antimuscarinic agent; respiratory system disorders, antiallergens, chronic obstructive pulmonary disease, adult respiratory distress syndrome, bronchitis | NOVARTIS AG (CH) | 2010-10-26 | — | — | US | disclosed |
| US-20100029705-A1 | Administering an aminoindanyl derivative and; a steroid, dopamine receptor agonist or an anticholinergic or antimuscarinic agent; respiratory system disorders, antiallergens, chronic obstructive pulmonary disease, adult respiratory distress syndrome, bronchitis | CUENOUD BERNARD | 2010-02-04 | — | — | US | disclosed |
| US-7622483-B2 | Administering an aminoindanyl derivative and; a steroid, dopamine receptor agonist or an anticholinergic or antimuscarinic agent; respiratory system disorders, antiallergens, chronic obstructive pulmonary disease, adult respiratory distress syndrome, bronchitis | NOVARTIS AG (CH) | 2009-11-24 | — | — | US | disclosed |
| EP-1183240-B1 | BETA2-ADRENOCEPTOR AGONISTS | NOVARTIS AG (CH) | 2009-08-19 | — | — | EP | disclosed |
| US-20050153957-A1 | Administering an aminoindanyl derivative and; a steroid, dopamine receptor agonist or an anticholinergic or antimuscarinic agent; respiratory system disorders, antiallergens, chronic obstructive pulmonary disease, adult respiratory distress syndrome, bronchitis | NOVARTIS AG (CH) | 2005-07-14 | — | — | US | disclosed |
| US-6878721-B1 | N-(partially hydrogenated fused carbocycle)-2-arylethylamine derivatives, e.g., 8-hydroxy-5-(1-hydroxy-2-(indan-2-ylamino)-ethyl)-1H-quinolin-2-one; treatment of obstructive or inflammatory | NOVARTIS AG (CH) | 2005-04-12 | — | — | US | disclosed |
| EP-1183240-A1 | BETA2-ADRENOCEPTOR AGONISTS | Novartis AG (CH) | 2002-03-06 | — | — | EP | disclosed |
| WO-2000075114-A1 | BETA2-ADRENOCEPTOR AGONISTS | NOVARTIS AG (CH) | 2000-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034509-A1 | Beta-2-Adrenoreceptor Agonists | ADRB2, ADRB1, ADRB3 | PIK3CG 4084/4885ADORA3 164/4885SIRT2 2309/4885 |
| US-20140066478-A1 | Beta2-Adrenoreceptor Agonists | ADRB2, ADRB1, ADRB3 | PIK3CG 4062/4885ADORA3 135/4885SIRT2 2400/4885 |
| US-20140343091-A1 | BETA2-ADRENOCEPTOR AGONISTS | ADRB2, ADRB1, ADRA2A | PIK3CG 3957/4885ADORA3 108/4885SIRT2 1859/4885 |
| US-20050153957-A1 | Administering an aminoindanyl derivative and; a steroid, dopamine receptor agonist or an anticholinergic or antimuscarinic agent; respiratory system disorders, antiallergens, chronic obstructive pulmonary disease, adult respiratory distress syndrome, bronchitis | ADRB3, ADRB2, ADRB1 | PIK3CG 4058/4885ADORA3 38/4885SIRT2 4527/4885 |
| US-20100029705-A1 | Administering an aminoindanyl derivative and; a steroid, dopamine receptor agonist or an anticholinergic or antimuscarinic agent; respiratory system disorders, antiallergens, chronic obstructive pulmonary disease, adult respiratory distress syndrome, bronchitis | ADRB3, ADRB2, ADRB1 | PIK3CG 4058/4885ADORA3 38/4885SIRT2 4527/4885 |
| US-20130231367-A1 | BETA2-ADRENORECEPTOR AGONISTS | ADRB2, ADRB1, ADRB3 | PIK3CG 4166/4885ADORA3 133/4885SIRT2 2345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.